Associated Papers
Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer.
Huang L et al.
Cancer, 2025
Specifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation.
Pang LL et al.
Neoplasia (new York, N.y.), 2024
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes.
Zhao W et al.
Bmc Medicine, 2023
36829178 (PubMed )
Supplement: 12916_2023_2768_MOESM1_ESM.docx
CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations.
Kang L et al.
Frontiers in Oncology, 2023
Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.
Pang LL et al.
Cancer, 2022
An unbiased in vitro screen for activating epidermal growth factor receptor mutations.
Chakroborty D et al.
The Journal of Biological Chemistry, 2019
Select a paper to view details